vs
Side-by-side financial comparison of HANMI FINANCIAL CORP (HAFC) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $71.2M, roughly 1.2× HANMI FINANCIAL CORP). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 17.1%). HANMI FINANCIAL CORP produced more free cash flow last quarter ($203.7M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 10.4%).
Hanmi Bank Corporation is a community bank headquartered in Los Angeles, California, with 35 branches and eight loan production offices in California, Texas, Illinois, New York, New Jersey and Virginia.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
HAFC vs IOVA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $71.2M | $86.8M |
| Net Profit | $21.2M | — |
| Gross Margin | — | 67.4% |
| Operating Margin | 29.8% | -84.7% |
| Net Margin | 29.8% | — |
| Revenue YoY | 17.1% | 17.7% |
| Net Profit YoY | 20.0% | — |
| EPS (diluted) | $0.70 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $71.2M | $86.8M | ||
| Q3 25 | $71.0M | $67.5M | ||
| Q2 25 | $65.2M | $60.0M | ||
| Q1 25 | $62.8M | $49.3M | ||
| Q4 24 | $60.8M | $73.7M | ||
| Q3 24 | $58.5M | $58.6M | ||
| Q2 24 | $56.7M | $31.1M | ||
| Q1 24 | $58.4M | $715.0K |
| Q4 25 | $21.2M | — | ||
| Q3 25 | $22.1M | $-91.3M | ||
| Q2 25 | $15.1M | $-111.7M | ||
| Q1 25 | $17.7M | $-116.2M | ||
| Q4 24 | $17.7M | — | ||
| Q3 24 | $14.9M | $-83.5M | ||
| Q2 24 | $14.5M | $-97.1M | ||
| Q1 24 | $15.2M | $-113.0M |
| Q4 25 | — | 67.4% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | — | 46.2% | ||
| Q2 24 | — | -0.8% | ||
| Q1 24 | — | — |
| Q4 25 | 29.8% | -84.7% | ||
| Q3 25 | 31.1% | -140.7% | ||
| Q2 25 | 23.2% | -189.8% | ||
| Q1 25 | 28.1% | -245.8% | ||
| Q4 24 | 29.1% | -117.5% | ||
| Q3 24 | 25.5% | -152.1% | ||
| Q2 24 | 25.5% | -327.6% | ||
| Q1 24 | 26.0% | -16464.6% |
| Q4 25 | 29.8% | — | ||
| Q3 25 | 31.1% | -135.3% | ||
| Q2 25 | 23.2% | -186.2% | ||
| Q1 25 | 28.1% | -235.5% | ||
| Q4 24 | 29.1% | — | ||
| Q3 24 | 25.5% | -142.7% | ||
| Q2 24 | 25.5% | -312.2% | ||
| Q1 24 | 26.0% | -15800.8% |
| Q4 25 | $0.70 | — | ||
| Q3 25 | $0.73 | — | ||
| Q2 25 | $0.50 | $-0.33 | ||
| Q1 25 | $0.58 | $-0.36 | ||
| Q4 24 | $0.58 | $-0.24 | ||
| Q3 24 | $0.49 | $-0.28 | ||
| Q2 24 | $0.48 | $-0.34 | ||
| Q1 24 | $0.50 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $297.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $796.4M | $698.6M |
| Total Assets | $7.9B | $913.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $297.0M | ||
| Q3 25 | — | $300.8M | ||
| Q2 25 | — | $301.2M | ||
| Q1 25 | — | $359.7M | ||
| Q4 24 | — | $323.8M | ||
| Q3 24 | — | $397.5M | ||
| Q2 24 | — | $412.5M | ||
| Q1 24 | — | $356.2M |
| Q4 25 | $796.4M | $698.6M | ||
| Q3 25 | $779.5M | $702.3M | ||
| Q2 25 | $762.8M | $698.5M | ||
| Q1 25 | $751.5M | $767.9M | ||
| Q4 24 | $732.2M | $710.4M | ||
| Q3 24 | $736.7M | $773.5M | ||
| Q2 24 | $707.1M | $768.5M | ||
| Q1 24 | $703.1M | $680.0M |
| Q4 25 | $7.9B | $913.2M | ||
| Q3 25 | $7.9B | $904.9M | ||
| Q2 25 | $7.9B | $907.4M | ||
| Q1 25 | $7.7B | $966.7M | ||
| Q4 24 | $7.7B | $910.4M | ||
| Q3 24 | $7.7B | $991.1M | ||
| Q2 24 | $7.6B | $964.3M | ||
| Q1 24 | $7.5B | $869.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $206.0M | $-52.6M |
| Free Cash FlowOCF − Capex | $203.7M | $-61.9M |
| FCF MarginFCF / Revenue | 286.2% | -71.3% |
| Capex IntensityCapex / Revenue | 3.2% | 10.7% |
| Cash ConversionOCF / Net Profit | 9.70× | — |
| TTM Free Cash FlowTrailing 4 quarters | $356.1M | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $206.0M | $-52.6M | ||
| Q3 25 | $146.9M | $-78.7M | ||
| Q2 25 | $-19.0M | $-67.4M | ||
| Q1 25 | $25.8M | $-103.7M | ||
| Q4 24 | $52.6M | $-73.3M | ||
| Q3 24 | $6.7M | $-59.0M | ||
| Q2 24 | $2.1M | $-98.4M | ||
| Q1 24 | $30.0M | $-122.3M |
| Q4 25 | $203.7M | $-61.9M | ||
| Q3 25 | $146.4M | $-89.5M | ||
| Q2 25 | $-19.6M | $-74.9M | ||
| Q1 25 | $25.6M | $-109.9M | ||
| Q4 24 | $49.9M | $-77.5M | ||
| Q3 24 | $6.5M | $-61.3M | ||
| Q2 24 | $1.3M | $-98.9M | ||
| Q1 24 | $29.2M | $-126.5M |
| Q4 25 | 286.2% | -71.3% | ||
| Q3 25 | 206.3% | -132.7% | ||
| Q2 25 | -30.0% | -124.9% | ||
| Q1 25 | 40.7% | -222.8% | ||
| Q4 24 | 82.1% | -105.1% | ||
| Q3 24 | 11.1% | -104.6% | ||
| Q2 24 | 2.3% | -317.9% | ||
| Q1 24 | 50.0% | -17685.3% |
| Q4 25 | 3.2% | 10.7% | ||
| Q3 25 | 0.8% | 16.1% | ||
| Q2 25 | 0.9% | 12.4% | ||
| Q1 25 | 0.4% | 12.6% | ||
| Q4 24 | 4.3% | 5.7% | ||
| Q3 24 | 0.4% | 3.9% | ||
| Q2 24 | 1.4% | 1.4% | ||
| Q1 24 | 1.4% | 583.4% |
| Q4 25 | 9.70× | — | ||
| Q3 25 | 6.66× | — | ||
| Q2 25 | -1.26× | — | ||
| Q1 25 | 1.46× | — | ||
| Q4 24 | 2.97× | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | 0.14× | — | ||
| Q1 24 | 1.98× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HAFC
Segment breakdown not available.
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
